ALT
Price
$8.25
Change
+$0.07 (+0.86%)
Updated
Dec 20 closing price
94 days until earnings call
AXSM
Price
$90.70
Change
+$0.96 (+1.07%)
Updated
Dec 20, 04:59 PM (EDT)
71 days until earnings call
Ad is loading...

ALT vs AXSM

Header iconALT vs AXSM Comparison
Open Charts ALT vs AXSMBanner chart's image
Altimmune
Price$8.25
Change+$0.07 (+0.86%)
Volume$4.9M
CapitalizationN/A
Axsome Therapeutics
Price$90.70
Change+$0.96 (+1.07%)
Volume$10.28K
CapitalizationN/A
ALT vs AXSM Comparison Chart
Loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AXSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALT vs. AXSM commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALT is a Hold and AXSM is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (ALT: $8.25 vs. AXSM: $90.73)
Brand notoriety: ALT and AXSM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALT: 141% vs. AXSM: 186%
Market capitalization -- ALT: $587.85M vs. AXSM: $4.4B
ALT [@Biotechnology] is valued at $587.85M. AXSM’s [@Biotechnology] market capitalization is $4.4B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALT’s FA Score shows that 0 FA rating(s) are green whileAXSM’s FA Score has 0 green FA rating(s).

  • ALT’s FA Score: 0 green, 5 red.
  • AXSM’s FA Score: 0 green, 5 red.
According to our system of comparison, AXSM is a better buy in the long-term than ALT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALT’s TA Score shows that 5 TA indicator(s) are bullish while AXSM’s TA Score has 5 bullish TA indicator(s).

  • ALT’s TA Score: 5 bullish, 4 bearish.
  • AXSM’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, both ALT and AXSM are a good buy in the short-term.

Price Growth

ALT (@Biotechnology) experienced а -8.64% price change this week, while AXSM (@Biotechnology) price change was +0.70% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

ALT is expected to report earnings on Mar 27, 2025.

AXSM is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AXSM($4.4B) has a higher market cap than ALT($588M). AXSM YTD gains are higher at: 13.997 vs. ALT (-26.667). ALT has higher annual earnings (EBITDA): -103.19M vs. AXSM (-298.59M). AXSM has more cash in the bank: 327M vs. ALT (139M). ALT has less debt than AXSM: ALT (1.77M) vs AXSM (192M). AXSM has higher revenues than ALT: AXSM (338M) vs ALT (52K).
ALTAXSMALT / AXSM
Capitalization588M4.4B13%
EBITDA-103.19M-298.59M35%
Gain YTD-26.66713.997-191%
P/E RatioN/AN/A-
Revenue52K338M0%
Total Cash139M327M43%
Total Debt1.77M192M1%
FUNDAMENTALS RATINGS
ALT vs AXSM: Fundamental Ratings
ALT
AXSM
OUTLOOK RATING
1..100
5060
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
87
Overvalued
PROFIT vs RISK RATING
1..100
7448
SMR RATING
1..100
9898
PRICE GROWTH RATING
1..100
4550
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AXSM's Valuation (87) in the Pharmaceuticals Other industry is in the same range as ALT (97) in the Miscellaneous Commercial Services industry. This means that AXSM’s stock grew similarly to ALT’s over the last 12 months.

AXSM's Profit vs Risk Rating (48) in the Pharmaceuticals Other industry is in the same range as ALT (74) in the Miscellaneous Commercial Services industry. This means that AXSM’s stock grew similarly to ALT’s over the last 12 months.

AXSM's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as ALT (98) in the Miscellaneous Commercial Services industry. This means that AXSM’s stock grew similarly to ALT’s over the last 12 months.

ALT's Price Growth Rating (45) in the Miscellaneous Commercial Services industry is in the same range as AXSM (50) in the Pharmaceuticals Other industry. This means that ALT’s stock grew similarly to AXSM’s over the last 12 months.

ALT's P/E Growth Rating (100) in the Miscellaneous Commercial Services industry is in the same range as AXSM (100) in the Pharmaceuticals Other industry. This means that ALT’s stock grew similarly to AXSM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALTAXSM
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
72%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
80%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
88%
Bearish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 20 days ago
77%
Declines
ODDS (%)
Bearish Trend 5 days ago
88%
Bearish Trend 4 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
75%
Aroon
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
74%
View a ticker or compare two or three
Ad is loading...
ALT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AXSM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RSRFX10.080.12
+1.20%
Reaves Infrastructure Fund Class Inst
GSPPX13.650.16
+1.19%
Goldman Sachs Strategic Growth P
NPNCX45.280.53
+1.18%
Neuberger Berman Large Cap Value C
GCICX13.24-0.04
-0.30%
Goldman Sachs Intl Eq Insghts C
FLUIX27.37-1.69
-5.81%
Fidelity Advisor Stk Selec Lg Cp Val I

AXSM and

Correlation & Price change

A.I.dvisor indicates that over the last year, AXSM has been loosely correlated with XENE. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if AXSM jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AXSM
1D Price
Change %
AXSM100%
+1.10%
XENE - AXSM
43%
Loosely correlated
-0.69%
ALT - AXSM
42%
Loosely correlated
+0.86%
CRNX - AXSM
42%
Loosely correlated
+1.63%
PLRX - AXSM
41%
Loosely correlated
-0.68%
MLTX - AXSM
40%
Loosely correlated
+0.56%
More